The effect of quercetin phase II metabolism on its MRP1 and MRP2 inhibiting potential

Biochemical Pharmacology

Volumn 74, Issue 2, 2007, Pages 345-351

  van Zanden, Jelmer J ^a   van der Woude, Hester ^a   Vaessen, Judith ^a   Usta, Mustafa ^b   Wortelboer, Heleen M ^b   Cnubben, Nicole H P ^a,b   Rietjens, Ivonne M C M ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b TNO   (Netherlands)

Author keywords

ABC transporters; Flavonoids; MRP1; MRP2; Phase II metabolism; Quercetin

Indexed keywords

ABC TRANSPORTER; FLAVONOID; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; QUERCETIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CHEMICAL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCURONIDATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CELL LINE, TUMOR; HUMANS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; QUERCETIN; RATS;

EID: 34250004857     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.04.002     Document Type: Article

References (45)

1. Fojo T., and Bates S. Strategies for reversing drug resistance. Oncogene 22 47 (2003) 7512-7523
2. Borst P., and Elferink R.O. Mammalian ABC transporters in health and disease. Annu Rev Biochem 71 (2002) 537-592
3. Loe D.W., Almquist K.C., Cole S.P., and Deeley R.G. ATP-dependent 17 beta-estradiol 17-(beta-d-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J Biol Chem 271 16 (1996) 9683-9689
4. Borst P., Zelcer N., and van Helvoort A. ABC transporters in lipid transport. Biochim Biophys Acta 1486 1 (2000) 128-144
5. Renes J., vries G.E., Jansen L.M., and Muller M. The (patho) physiological functions of the MRP family. Drug Resist Updat 3 (2000) 289-302
6. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258 5088 (1992) 1650-1654
7. Konig J., Nies A.T., Cui Y., Leier I., and Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1461 2 (1999) 377-394
8. Hooijberg J.H., Broxterman H.J., Heijn M., Fles D.L., Lankelma J., and Pinedo H.M. Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. FEBS Lett 413 2 (1997) 344-348
9. Conseil G., Baubichon-Cortay H., Dayan G., Jault J.M., Barron D., and Di Pietro A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 95 17 (1998) 9831-9836
10. Zhang S., Yang X., and Morris M.E. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 65 5 (2004) 1208-1216
11. Leslie E.M., Mao Q., Oleschuk C.J., Deeley R.G., and Cole S.P. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol Pharmacol 59 5 (2001) 1171-1180
12. Zanden van J.J., Wortelboer H.M., Bijlsma S., Punt A., Usta M., Bladeren P.J., et al. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem Pharmacol 69 4 (2005) 699-708
13. Zanden van J.J., Geraets L., Wortelboer H.M., Bladeren P.J., Rietjens I.M.C.M., and Cnubben N.H.P. Structural requirements for the flavonoid mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells. Biochem Pharmacol 67 8 (2004) 1607-1617
14. Schutte M.E., Van de Sandt J.J.M., Alink G.M., Groten J.P., and Rietjens I.M.C.M. Myricetin stimulates the absorption of the pro-carcinogen PhIP. Cancer Lett 231 (2006) 36-42
15. Kitagawa S., Nabekura T., Takahashi T., Nakamura Y., Sakamoto H., Tano H., et al. Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol Pharm Bull 28 (2005) 2274-2278
16. Walgren R.A., Karnaky K.J.J., Lindenmayer G.E., and Walle T. Efflux of dietary flavonoid quercetin-4′-glucoside across human Intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J Pharmacol Exp Ther 294 (2000) 830-836
17. Zhang S., and Morris M.E. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304 (2003) 1258-1267
18. Lania-Pietrzak B., Michalak K., Hendrich A.B., Mosiadz D., Grynkiewicz G., Motohashi N., et al. Modulation of MRP1 protein transport by plant, and synthetically modified flavonoids. Life Sci 77 (2005) 1879-1891
19. Nguyen H., Zhang S., and Morris M.E. Effect of flavonoids on MRP1-mediated transport in panc-1 cells. J Pharm Sci 92 (2003) 250-257
20. Wu C.-P., Calcagno A.M., Hladky S.B., Ambudkar S.V., and Barrand M.A. Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J 272 (2005) 4725-4740
21. Ahmed-Belkacem A., Pozza A., Muñoz-Martinez F., Bates S.E., Castanys S., Gamarro F., et al. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res 65 (2005) 4852-4860
22. Cooray H.C., Janvilisri T., Van Veen H.W., Hladky B., and Barrand M.A. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun 317 (2004) 269-275
23. Yoshikawa M., Ikegami Y., Sano K., Yoshida H., Mitomo H., Sawada S., et al. Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J Exp Ther Oncol 4 (2004) 25-35
24. Brand W., Schutte M.E., Williamson G., Zanden van J.J., Cnubben N.H.P., Groten J.P., et al. Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomed Pharmacother 60 9 (2006) 508-519
25. Rice-Evans C., and Flavonoids. isoflavones: absorption, metabolism, and bioactivity. Free Radic Biol Med 36 7 (2004) 827-828
26. Spencer J.P., Abd-el-Mohsen M.M., and Rice-Evans C. Cellular uptake and metabolism of flavonoids and their metabolites: implications for their bioactivity. Arch Biochem Biophys 423 1 (2004) 148-161
27. Day A.J., Bao Y., Morgan M.R., and Williamson G. Conjugation position of quercetin glucuronides and effect on biological activity. Free Radic Biol Med 29 12 (2000) 1234-1243
28. Williamson G., Day A.J., Plumb G.W., and Couteau D. Human metabolic pathways of dietary flavonoids and cinnamates. Biochem Soc Trans 28 2 (2000) 16-22
29. Hertog M.G., Hollman P.C., Katan M.B., and Kromhout D. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in the Netherlands. Nutr Cancer 20 1 (1993) 21-29
30. Day A.J., DuPont M.S., Ridley S., Rhodes M., Rhodes M.J., Morgan M.R., et al. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver beta-glucosidase activity. FEBS Lett 436 1 (1998) 71-75
31. Kim D.H., Jung E.A., Sohng I.S., Han J.A., Kim T.H., and Han M.J. Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Arch Pharm Res 21 1 (1998) 17-23
32. Day A.J., Mellon F., Barron D., Sarrazin G., Morgan M.R., and Williamson G. Human metabolism of dietary flavonoids: identification of plasma metabolites of quercetin. Free Radic Res 35 6 (2001) 941-952
33. Manach C., Morand C., Crespy V., Demigne C., Texier O., Regerat F., et al. Quercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties. FEBS Lett 426 3 (1998) 331-336
34. Morand C., Crespy V., Manach C., Besson C., Demigne C., and Remesy C. Plasma metabolites of quercetin and their antioxidant properties. Am J Physiol 275 1 Pt 2 (1998) R212-R219
35. Van der Woude H., Boersma M.G., Vervoort J., and Rietjens I.M.C.M. Identification of 14 quercetin phase II mono- and mixed conjugates and their formation by rat and human phase II in vitro model systems. Chem Res Toxicol 17 11 (2004) 1520-1530
36. Wortelboer H.M., Usta M., van der Velde A.E., Boersma M.G., Spenkelink B., van Zanden J.J., et al. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. Chem Res Toxicol 16 12 (2003) 1642-1651
37. Zaman G.J., Cnubben N.H., van Bladeren P.J., Evers R., and Borst P. Transport of the glutathione conjugate of ethacrynic acid by the human multidrug resistance protein MRP. FEBS Lett 391 1-2 (1996) 126-130
38. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
39. Bakos E., Hegedus T., Hollo Z., Welker E., Tusnady G.E., Zaman G.J., et al. Membrane topology and glycosylation of the human multidrug resistance-associated protein. J Biol Chem 271 21 (1996) 12322-12326
40. Gao M., Loe D.W., Grant C.E., Cole S.P., and Deeley R.G. Reconstitution of ATP-dependent leukotriene C4 transport by co-expression of both half-molecules of human multidrug resistance protein in insect cells. J Biol Chem 271 44 (1996) 27782-27787
41. Rice-Evans C., Spencer J.P., Schroeter H., and Rechner A.R. Bioavailability of flavonoids and potential bioactive forms in vivo. Drug Metabol Drug Interact 17 1-4 (2000) 291-310
42. Walle U.K., Galijatovic A., and Walle T. Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem Pharmacol 58 3 (1999) 431-438
43. Walgren R.A., Karnaky Jr. K.J., Lindenmayer G.E., and Walle T. Efflux of dietary flavonoid quercetin 4′-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J Pharmacol Exp Ther 294 3 (2000) 830-836
44. Sesink A.L., Arts I.C., de Boer V.C., Breedveld P., Schellens J.H., Hollman P.C., et al. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol Pharmacol 67 6 (2005) 1999-2006
45. Ferry D.R., Smith A., Malkhandi J., Fyfe D.W., deTakats P.G., Anderson D., et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Can Res 2 4 (1996) 659-668